

November 10, 2022

<p>The Secretary Listing Department, BSE Limited, 1st Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400001 Scrip Code: 540975</p>	<p>The Manager, Listing Department, The National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ASTERDM</p>
--	---

Dear Sir/Madam,

Sub: Press Release on unaudited financial results for the quarter and half year ended September 30, 2022

With reference to the captioned subject, please find enclosed press release in relation to the unaudited financial results of the Company for the quarter and half year ended September 30, 2022.

Kindly take the above said information on record as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thank you

For Aster DM Healthcare Limited

HEMISH
PURUSHOTTAM

Digitally signed by
HEMISH PURUSHOTTAM
Date: 2022.11.10
18:54:07 +05'30'

Hemish Purushottam
Company Secretary and Compliance Officer

Aster DM Healthcare Q2 FY23 Results

**Consolidated revenue from operations up 12% YoY to Rs. 2,816 Crs
EBITDA at Rs. 319 Crs. and PAT (Post NCI) at 46 Crs.**

**India revenue from operations up 24% YoY to Rs. 757 Crs., EBITDA up
24% YoY to Rs. 127 Crs. and PAT (Post NCI) up 119% YoY to Rs. 50 Crs.**

Bangalore, November 10, 2022: Aster DM Healthcare, one of the largest private healthcare service providers in GCC and in India, today announced its financial results for the quarter ended September 30, 2022.

KEY HIGHLIGHTS OF THE QUARTER

- Operational Revenue increased by 12% Y-o-Y to Rs. 2,816 Crs. compared to Rs. 2,504 Crs. in Q2 FY 22
- EBITDA (excluding other income) was at Rs. 319 Crs. as compared to Rs. 343 Crs in Q2 FY 22. Excluding losses due to new hospitals, EBITDA stands at Rs. 342 Cr.
- PAT (Pre- Non-Controlling Interest) was at Rs. 54 Crs. compared to Rs. 128 Crs. in Q2 FY 22. Adjusting for losses due to new hospitals, PAT (Pre- Non-Controlling Interest) was at Rs. 96 Crs.

KEY HIGHLIGHTS OF THE PERIOD (FY23 H1)

- Operational Revenue increased by 12% Y-o-Y to Rs. 5,478 Crs. compared to Rs. 4,876 Crs. in H1 FY 22
- EBITDA (excluding other income) was at Rs. 611 Crs. as compared to Rs. 624 Crs in H1 FY 22. Excluding losses due to new hospitals, EBITDA stands at Rs. 654 Cr.
- PAT (Pre- Non-Controlling Interest) was at Rs. 134 Crs. compared to Rs. 187 Crs. in H1 FY 22. Adjusting for losses due to new hospitals and one-time other income, PAT (Pre- Non-Controlling Interest) was at Rs. 184 Crs.

Commenting on the performance for Q2 FY23, Dr. Azad Moopen, Founder Chairman and Managing Director, Aster DM Healthcare, said:

"In Q2, we had a revenue growth of 12% on a consolidated basis. Revenue in the GCC increased 9% over last year while strong growth momentum in India continued, with revenues growing 24% over Q2 FY 22.

In the GCC region, we have inaugurated the 101- bed Aster Hospital in Sharjah in October 2022, the soft launch of which was done in May 2022. The hospital has a team of experienced doctors with proven clinical excellence and support staff to offer exceptional patient care and medical outcomes. The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopedics, Neurology, Cardiology,

Paediatrics, General Surgery, and Urology. The plan is to add many tertiary care treatments to the bouquet of services in future. In Oman, we had a soft launch of the 181 bedded multispeciality hospital Aster Royal Hospital in Muscat, located next to the Aster Al Raffah Hospital.

We entered into a Hospital Operation and Management Agreement (O&M) with Narayanadri Hospitals and Research Institute Private Limited (NHRI), Tirupati, Andhra Pradesh recently. It is a 150-bedded multi-Specialty hospital situated at Tirupati, Andhra Pradesh. With this addition, we have added 290 beds on O&M asset-light model in the current financial year. We expect to add another 2 to 3 hospitals of around 300 to 400 beds before the end of the current financial year. While this is a low margin business, this has also very low capex and shall help in increasing our ROCE. It will also help to increase the referral of cases to our flagship hospitals."

Commenting on Aster's New Business Initiatives, Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare, said:

"Aster DM Healthcare has launched its pharmacy operations in Saudi Arabia through a tie up with the Al Hokair Holding Group. The partners will create a network of 250 plus Aster pharmacies in the Kingdom in the next 5 years. The partnership plans to open in high-street locations, communities and malls beginning with Riyadh. As Phase 2, the aim is to set up pharmaceutical manufacturing in the Kingdom.

Medcare announced its expansion into the premium wellness and beauty care segment with the acquisition of 60 % share in Skin 111 Clinics. Skin111 Clinics is an award-winning premium chain of aesthetic and wellness centres. This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network in the UAE. With this agreement, Skin111 Clinic's unique offerings will be incorporated into Medcare service portfolio giving it an edge in the aesthetics and wellness segments, a key driver of the UAE's growing medical tourism sector."

About Aster DM Healthcare

Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 30 hospitals, 121 clinics, 459* pharmacies, 19 labs and 140 patient experience centers in seven countries, including India. We have over 28,400 plus dedicated staff including 3,622 doctors and 8,095 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: "We'll treat you well." We reach out to all economic segments in the GCC states through our differentiated healthcare services across the "Aster", "Medcare" and "Access" brands.

For more information about us, please visit www.asterdmhealthcare.com or contact:

Investor Relations Department Aster DM Healthcare investors@asterdmhealthcare.com	Lavanya Mandal Head of PR and Internal Communication Aster DM Healthcare Tel: +971 52 8126577 lavanya.mandal@asterdmhealthcare.com
---	--

* Including 214 Pharmacies in India operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster.

DISCLAIMER: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Aster DM Healthcare will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.